

Anne Davidson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4350110/publications.pdf>

Version: 2024-02-01

123
papers

7,435
citations

70961

41
h-index

56606

83
g-index

138
all docs

138
docs citations

138
times ranked

7751
citing authors

#	ARTICLE	IF	CITATIONS
1	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
2	Context-dependent induction of autoimmunity by TNF signaling deficiency. <i>JCI Insight</i> , 2022, 7, .	2.3	2
3	Urine Proteomics and Renal <sc>Single-Cell</sc> Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	2.9	38
4	Rubicon promotes rather than restricts murine lupus and is not required for LC3-associated phagocytosis. <i>JCI Insight</i> , 2022, 7, .	2.3	3
5	Promise and complexity of lupus mouse models. <i>Nature Immunology</i> , 2021, 22, 683-686.	7.0	5
6	Renal Mononuclear Phagocytes in Lupus Nephritis. <i>ACR Open Rheumatology</i> , 2021, 3, 442-450.	0.9	10
7	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
8	Reversible dysregulation of renal circadian rhythm in lupus nephritis. <i>Molecular Medicine</i> , 2021, 27, 99.	1.9	4
9	509...The localization of novel macrophage subsets in class III and IV lupus nephritis kidney sections. , 2021, , .		0
10	Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche. <i>Blood</i> , 2021, 138, 1989-1989.	0.6	0
11	General Features of Autoimmune Disease. , 2020, , 17-44.		8
12	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1505-1513.	0.9	3
13	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020, 72, 233-242.	1.5	17
14	Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. <i>Nature Reviews Rheumatology</i> , 2020, 16, 255-267.	3.5	74
15	Integrated urine proteomics and renal single-cell genomics identify an IFN- γ response gradient in lupus nephritis. <i>JCI Insight</i> , 2020, 5, .	2.3	57
16	Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry. <i>Blood</i> , 2020, 136, 33-34.	0.6	5
17	Efficacy of the Combination of Metformin and CTLA4Ig in the (NZB \times NZW)F1 Mouse Model of Lupus Nephritis. <i>ImmunoHorizons</i> , 2020, 4, 319-331.	0.8	14
18	BAFF inhibition in SLE...Is tolerance restored?. <i>Immunological Reviews</i> , 2019, 292, 102-119.	2.8	38

#	ARTICLE	IF	CITATIONS
19	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
20	204â€¦The immune cell landscape in kidneys of lupus nephritis patients. , 2019, , .		2
21	AB0167â€¦SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCASIAN PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY. , 2019, , .		0
22	205â€¦Single cell RNA expression in lupus nephritis comparing african-american and caucasian patients identifies differential expression of type I interferon pathway. , 2019, , .		0
23	Lupus nephritis: challenges and progress. <i>Current Opinion in Rheumatology</i> , 2019, 31, 682-688.	2.0	46
24	Age-associated B cells acquire a new wrinkle. <i>Nature Immunology</i> , 2018, 19, 317-318.	7.0	4
25	Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. <i>JCI Insight</i> , 2018, 3, .	2.3	44
26	TD-02â€¦Kidney tissue damage in mice with single and combined abnormalities in complement, interferon and apoptotic cell clearance. , 2018, , .		0
27	Emerging areas for therapeutic discovery in SLE. <i>Current Opinion in Immunology</i> , 2018, 55, 1-8.	2.4	6
28	Renal Macrophages and Dendritic Cells in SLE Nephritis. <i>Current Rheumatology Reports</i> , 2017, 19, 81.	2.1	48
29	Bim suppresses the development of SLE by limiting myeloid inflammatory responses. <i>Journal of Experimental Medicine</i> , 2017, 214, 3753-3773.	4.2	27
30	A systems approach to renal inflammation in SLE. <i>Clinical Immunology</i> , 2017, 185, 109-118.	1.4	13
31	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€”The Berlin Roadmap. <i>Kidney International Reports</i> , 2016, 1, 327-339.	0.4	1
32	Immune Monitoring of Trans-endothelial Transport by Kidney-Resident Macrophages. <i>Cell</i> , 2016, 166, 991-1003.	13.5	154
33	Fellow use of medical jargon correlates inversely with patient and observer perceptions of professionalism: results of a rheumatology OSCE (ROSCE) using challenging patient scenarios. <i>Clinical Rheumatology</i> , 2016, 35, 2093-2099.	1.0	13
34	What is damaging the kidney in lupus nephritis?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 143-153.	3.5	220
35	The Effect of BAFF Inhibition on Autoreactive B-Cell Selection in Murine Systemic Lupus Erythematosus. <i>Molecular Medicine</i> , 2016, 22, 173-182.	1.9	21
36	Sustaining the Rheumatology Research Enterprise. <i>Arthritis Care and Research</i> , 2015, 67, 1187-1190.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Defects in Germinal Center Selection in SLE. <i>Frontiers in Immunology</i> , 2015, 6, 425.	2.2	36
38	Molecular studies of lupus nephritis kidneys. <i>Immunologic Research</i> , 2015, 63, 187-196.	1.3	15
39	TLR7 Influences Germinal Center Selection in Murine SLE. <i>PLoS ONE</i> , 2015, 10, e0119925.	1.1	16
40	Structure and Function of Renal Macrophages and Dendritic Cells From Lupus-Prone Mice. <i>Arthritis and Rheumatology</i> , 2014, 66, 1596-1607.	2.9	58
41	Editorial: Autoimmunity to Vimentin and Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3251-3254.	2.9	12
42	General Features of Autoimmune Disease. , 2014, , 19-37.		11
43	Interferon alpha on NZM2328.Lc1R27: Enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure. <i>Clinical Immunology</i> , 2014, 154, 66-71.	1.4	27
44	Identification of Stage-Specific Genes Associated With Lupus Nephritis and Response to Remission Induction in (NZB × NZW)F1 and NZM2410 Mice. <i>Arthritis and Rheumatology</i> , 2014, 66, 2246-2258.	2.9	50
45	Identification of stage-specific genes associated with lupus nephritis and response to remission induction in NZB/W and NZM2410 mice. <i>Arthritis Research and Therapy</i> , 2014, 16, A21.	1.6	0
46	BAFF and APRIL and Their Receptors. , 2014, , 181-187.		0
47	IFN- γ Inducible Models of Murine SLE. <i>Frontiers in Immunology</i> , 2013, 4, 306.	2.2	43
48	Pathogenetic Mechanisms in Lupus Nephritis. , 2013, , 237-255.		4
49	The Multiple Chemokine-Binding Bovine Herpesvirus 1 Glycoprotein G (BHV1gG) Inhibits Polymorphonuclear Cell but Not Monocyte Migration into Inflammatory Sites. <i>Molecular Medicine</i> , 2013, 19, 276-285.	1.9	7
50	Comparative Transcriptional Profiling of 3 Murine Models of SLE Nephritis Reveals Both Unique and Shared Regulatory Networks. <i>PLoS ONE</i> , 2013, 8, e77489.	1.1	41
51	The Yaa Locus and IFN- γ Fine-Tune Germinal Center B Cell Selection in Murine Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2012, 189, 4305-4312.	0.4	26
52	Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-2.	3.3	16
53	Taming lupus—a new understanding of pathogenesis is leading to clinical advances. <i>Nature Medicine</i> , 2012, 18, 871-882.	15.2	390
54	Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2975-2985.	6.7	129

#	ARTICLE	IF	CITATIONS
55	Anti- γ -tumor necrosis factor γ treatment of interferon- γ -induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation. <i>Arthritis and Rheumatism</i> , 2012, 64, 3399-3408.	6.7	34
56	B-cell activating factor targeted therapy and lupus. <i>Arthritis Research and Therapy</i> , 2012, 14, S2.	1.6	27
57	Cross-Species Transcriptional Network Analysis Defines Shared Inflammatory Responses in Murine and Human Lupus Nephritis. <i>Journal of Immunology</i> , 2012, 189, 988-1001.	0.4	196
58	The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2012, 14, 295-302.	2.1	31
59	Analysis of Renal Mononuclear Phagocytes in Murine Models of SLE. <i>Methods in Molecular Biology</i> , 2012, 900, 207-232.	0.4	7
60	Process and Analysis of Kidney Infiltrates by Flow Cytometry from Murine Lupus Nephritis. <i>Bio-protocol</i> , 2012, 2, .	0.2	2
61	From the Large Scale Expression Analysis of Lupus Nephritis to Targeted Molecular Medicine. <i>Journal of Data Mining in Genomics & Proteomics</i> , 2012, 03, .	0.5	10
62	Isolation of Dendritic Cells and Macrophages from the Murine Kidneys of Lupus by Cell Sorter. <i>Bio-protocol</i> , 2012, 2, .	0.2	0
63	BAFF and selection of autoreactive B cells. <i>Trends in Immunology</i> , 2011, 32, 388-394.	2.9	141
64	BAFF inhibition: A new class of drugs for the treatment of autoimmunity. <i>Experimental Cell Research</i> , 2011, 317, 1270-1277.	1.2	58
65	Plasma cells in systemic lupus erythematosus: The long and short of it all. <i>European Journal of Immunology</i> , 2011, 41, 588-591.	1.6	41
66	Interferon- γ accelerates murine systemic lupus erythematosus in a T cell-dependent manner. <i>Arthritis and Rheumatism</i> , 2011, 63, 219-229.	6.7	117
67	IFN- γ Confers Resistance of Systemic Lupus Erythematosus Nephritis to Therapy in NZB/W F1 Mice. <i>Journal of Immunology</i> , 2011, 187, 1506-1513.	0.4	44
68	A Unique Hybrid Renal Mononuclear Phagocyte Activation Phenotype in Murine Systemic Lupus Erythematosus Nephritis. <i>Journal of Immunology</i> , 2011, 186, 4994-5003.	0.4	132
69	BAFF/APRIL Inhibition Decreases Selection of Naive but Not Antigen-Induced Autoreactive B Cells in Murine Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 187, 6571-6580.	0.4	27
70	Future advances in pharmacogenomics: BAFF, APRIL and plasma cells. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 281-285.	0.3	1
71	Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2010, 62, 201-210.	6.7	198
72	Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. <i>Arthritis and Rheumatism</i> , 2010, 62, 1457-1468.	6.7	92

#	ARTICLE	IF	CITATIONS
73	Targeting BAFF in autoimmunity. <i>Current Opinion in Immunology</i> , 2010, 22, 732-739.	2.4	99
74	Activated basophils give lupus a booster shot. <i>Nature Medicine</i> , 2010, 16, 635-636.	15.2	8
75	Enhanced Selection of High Affinity DNA-Reactive B Cells Following Cyclophosphamide Treatment in Mice. <i>PLoS ONE</i> , 2010, 5, e8418.	1.1	26
76	Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 3012-3017.	3.3	133
77	Lupus nephritis: lessons from murine models. <i>Nature Reviews Rheumatology</i> , 2010, 6, 13-20.	3.5	82
78	Interferon- α treatment of female (NZW \times BXSB)F ₁ mice mimics some but not all features associated with the <i>Yaa</i> mutation. <i>Arthritis and Rheumatism</i> , 2009, 60, 1096-1101.	6.7	46
79	B cells twist and shout. <i>Immunology and Cell Biology</i> , 2009, 87, 512-513.	1.0	2
80	Inhibitory short synthetic oligodeoxynucleotides and lupus. <i>Arthritis Research and Therapy</i> , 2009, 11, 116.	1.6	2
81	Prevention of murine antiphospholipid syndrome by BAFF blockade. <i>Arthritis and Rheumatism</i> , 2008, 58, 2824-2834.	6.7	101
82	Targeting of the immune system in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e2.	1.6	30
83	BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?. <i>Immunological Reviews</i> , 2008, 223, 156-174.	2.8	55
84	OR.14. IFN- α Accelerates SLE in a T Cell Dependent and BAFF Independent Manner. <i>Clinical Immunology</i> , 2008, 127, S8-S9.	1.4	0
85	Tinea versicolor associated with etanercept therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, S99-S100.	0.6	11
86	Activated Renal Macrophages Are Markers of Disease Onset and Disease Remission in Lupus Nephritis. <i>Journal of Immunology</i> , 2008, 180, 1938-1947.	0.4	214
87	Contribution of BAFF and DNA-containing Immune Complexes to the Generation of DNA-reactive B cells. <i>FASEB Journal</i> , 2008, 22, 668.17.	0.2	0
88	Autoimmunity Stimulated by Adoptively Transferred Dendritic Cells Is Initiated by Both $\text{CD}4^+$ and $\text{CD}8^+$ T Cells but Does Not Require MyD88 Signaling. <i>Journal of Immunology</i> , 2007, 179, 5819-5828.	0.4	7
89	Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. <i>Carcinogenesis</i> , 2007, 28, 2614-2623.	1.3	59
90	Activated Interstitial Macrophages are Important Mediators of SLE Nephritis. <i>Clinical Immunology</i> , 2007, 123, S88.	1.4	0

#	ARTICLE	IF	CITATIONS
91	General Features of Autoimmune Disease. , 2006, , 25-36.		5
92	Pathogenesis and treatment of systemic lupus erythematosus nephritis. Current Opinion in Internal Medicine, 2006, 5, 631-638.	1.5	28
93	Inhibition of <i>Helicobacter hepaticus</i> -Induced Colitis by IL-10 Requires the p50/p105 Subunit of NF- κ B. Journal of Immunology, 2006, 177, 7332-7339.	0.4	37
94	New immune modulatory drugs for systemic lupus erythematosus—what can we expect?. Nature Clinical Practice Rheumatology, 2006, 2, 638-639.	3.2	1
95	Similarities and differences between selective and nonselective BAFF blockade in murine SLE. Journal of Clinical Investigation, 2006, 116, 724-734.	3.9	196
96	Cross-reactivity of human lupus anti-DNA antibodies with γ -actinin and nephritogenic potential. Arthritis and Rheumatism, 2005, 52, 522-530.	6.7	105
97	Expansion and Hyperactivity of CD1d-Restricted NKT Cells during the Progression of Systemic Lupus Erythematosus in (New Zealand Black \times New Zealand White)F1 Mice. Journal of Immunology, 2005, 175, 763-770.	0.4	62
98	Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3524-3534.	0.4	128
99	BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. European Journal of Immunology, 2004, 34, 2750-2759.	1.6	119
100	CTLA4Ig Prevents Initiation but not Evolution of Anti-phospholipid Syndrome in NZW/BXSB Mice. Autoimmunity, 2004, 37, 445-451.	1.2	47
101	The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Research, 2004, 6, 197.	2.0	35
102	Induction of B7-1 in podocytes is associated with nephrotic syndrome. Journal of Clinical Investigation, 2004, 113, 1390-1397.	3.9	495
103	Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 495-506.	6.7	81
104	Costimulatory Blockade in the Treatment of Murine Systemic Lupus Erythematosus (SLE). Annals of the New York Academy of Sciences, 2003, 987, 188-198.	1.8	35
105	Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition. Journal of Immunology, 2003, 171, 489-497.	0.4	144
106	Mechanism of Action of Combined Short-Term CTLA4Ig and Anti-CD40 Ligand in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2002, 168, 2046-2053.	0.4	96
107	The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 1554-1562.	6.7	153
108	Autoimmune Diseases. New England Journal of Medicine, 2001, 345, 340-350.	13.9	965

#	ARTICLE	IF	CITATIONS
109	THE EFFECT OF CD28/B7 BLOCKADE ON ALLOREACTIVE T AND B CELLS AFTER LIVER CELL TRANSPLANTATION 1. Transplantation, 2001, 71, 801-811.	0.5	21
110	CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. Journal of Clinical Investigation, 2000, 106, 91-101.	3.9	147
111	An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM) Tj ETQq1 1 0.784314 rgBT /Overlock 16	6.7	16
112	A Rheumatoid Factor Specific Mimotope Identified by a Peptide Display Library. Autoimmunity, 1999, 30, 131-142.	1.2	9
113	Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology, 1998, 27, 1368-1376.	3.6	93
114	Somatic Mutation. , 1998, , 2192-2193.		0
115	Molecular Characterization of Monoclonal IgM Derived from Human B Cell Lines Expressing the 4C9 Rheumatoid Factor Associated Idiotype. Autoimmunity, 1995, 20, 171-183.	1.2	4
116	Expression of Rheumatoid Factor Idiotypes 17.109, 6b6.6 and 4c9 in the Sera of Pima Indians. Autoimmunity, 1994, 18, 251-258.	1.2	6
117	Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy. FASEB Journal, 1992, 6, 2836-2842.	0.2	32
118	Speculation on the Role of Somatic Mutation in the Generation of Anti-DNA Antibodies. Annals of the New York Academy of Sciences, 1986, 475, 174-179.	1.8	4
119	Use of anti-idiotypic antibodies to explore genetic mechanisms of production of anti-DNA antibodies. Cellular Immunology, 1986, 99, 44-52.	1.4	5
120	ORIGINS OF ANTI-DNA ANTIBODIES. , 1986, , 277-287.		3
121	Bone crisis of Gaucher's disease due to bone ischemia: A case report. Arthritis and Rheumatism, 1985, 28, 218-221.	6.7	6
122	IgG binding enhances DNAase I sensitivity of N-acetoxy-N-2-acetylaminofluorene-modified \hat{I} X-174 RF DNA. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1985, 825, 80-88.	2.4	1
123	HYDRALAZINE-INDUCED LUPUS: NO ASSOCIATION WITH HLA-DR4. Lancet, The, 1984, 323, 462.	6.3	36